Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27914912 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL9828480 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL27897570 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL28801700 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL11298285 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL3325908 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL3092823 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL381494 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL3326811 | 1.00 | OPRM1 (0.48) | OPRM1LAP3SPHK1MAPTTP53 | |
| SCHEMBL1063647 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578566-B1 | BIOCIDAL PEPTIDE AND PREPARATION BASED THEREON | VERTA RES PRODUCTION COMPANY LTD (RU) | 2023-07-19 | — | — | EP | claimed |
| CN-112300250-B | Anidulafungin analogue and preparation method thereof | 上海医药工业研究院 | 2024-03-19 | — | — | CN | disclosed |
| EP-3578566-B1 | BIOCIDAL PEPTIDE AND PREPARATION BASED THEREON | VERTA RES PRODUCTION COMPANY LTD (RU) | 2023-07-19 | — | — | EP | disclosed |
| CN-110650970-B | Antibacterial peptide and medicine thereof | 长春艾迪尔医用科技发展有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4159795-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD-Therapeutics GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-3145984-B1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD THERAPEUTICS GMBH (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-11059860-B2 | Biocidal peptide and preparation based thereon | VERTA RESEARCH-PRODUCTION COMPANY LTD (RU) | 2021-07-13 | — | — | US | disclosed |
| US-11045560-B2 | Therapeutic conjugates with sulfated dendrimers for intracellular targeting | ICD-THERAPEUTICS GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| US-20170182193-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD-THERAPEUTICS GMBH (DE) | 2017-06-29 | — | — | US | disclosed |
| EP-2483679-A1 | SENSORS WITH THROMBORESISTANT COATING | Glumetrics, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041546-A1 | SENSORS WITH THROMBORESISTANT COATING | GLUMETRICS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045560-B2 | Therapeutic conjugates with sulfated dendrimers for intracellular targeting | CD44, SELE, SLC10A6 | OPRM1 453/4885LAP3 1716/4885SPHK1 1907/4885 |
| US-20170182193-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | CD44, SLC10A6, SELE | OPRM1 533/4885LAP3 1694/4885SPHK1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.